Pharvaris NV
NASDAQ:PHVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharvaris NV
NASDAQ:PHVS
|
NL |
|
Woodward Inc
F:WW1
|
US |
|
I
|
International Seaways Inc
F:IS5
|
US |
|
U
|
United Utilities Group PLC
F:UUEA
|
UK |
|
S
|
Scentre Group
SWB:59S
|
AU |
|
S
|
Serco Group PLC
SWB:SEO
|
UK |
|
Greenbrier Companies Inc
NYSE:GBX
|
US |
|
Peach Property Group AG
LSE:0QOJ
|
CH |
|
H
|
Herbalife Ltd
XMUN:HOO
|
KY |
|
F
|
Fifth Third Bancorp
XBER:FFH
|
US |
|
L
|
Liberty Global PLC
F:1LGC
|
UK |
|
S
|
Sumitomo Corp
OTC:SSUMF
|
JP |
|
Panasonic Holdings Corp
TSE:6752
|
JP |
Pharvaris NV
Pharvaris is a clinical-stage biotechnology company focused on hereditary angioedema, or HAE, a rare condition that causes sudden and painful swelling attacks. It is developing oral medicines designed to block the bradykinin pathway, which plays a central role in HAE symptoms. Its main product candidates are meant to be taken as pills, instead of injections or infusions, which is the key difference in its approach. The company does not sell an approved drug yet. It spends most of its time and money on research, clinical trials, and regulatory work to get its HAE treatments approved. If successful, it would make money by selling those medicines through the prescription drug market, usually through specialty pharmacies and healthcare providers that treat patients with rare diseases. Pharvaris serves patients with HAE and the doctors who manage that disease, but its business model is really that of a drug developer rather than a drug manufacturer or distributor. That makes it different from large pharmaceutical companies with broad product lines: its value depends on proving that one focused set of oral HAE therapies is safe, effective, and easier for patients to use than existing treatment options.
Pharvaris is a clinical-stage biotechnology company focused on hereditary angioedema, or HAE, a rare condition that causes sudden and painful swelling attacks. It is developing oral medicines designed to block the bradykinin pathway, which plays a central role in HAE symptoms. Its main product candidates are meant to be taken as pills, instead of injections or infusions, which is the key difference in its approach.
The company does not sell an approved drug yet. It spends most of its time and money on research, clinical trials, and regulatory work to get its HAE treatments approved. If successful, it would make money by selling those medicines through the prescription drug market, usually through specialty pharmacies and healthcare providers that treat patients with rare diseases.
Pharvaris serves patients with HAE and the doctors who manage that disease, but its business model is really that of a drug developer rather than a drug manufacturer or distributor. That makes it different from large pharmaceutical companies with broad product lines: its value depends on proving that one focused set of oral HAE therapies is safe, effective, and easier for patients to use than existing treatment options.
